| IPO Company Profile © ipodata.com |
| Message Board | SEC Filings | Peer IPO Companies |
| Acusphere, Inc. |
| 38 Sidney Street, Cambridge, MA 02139 * (617) 577-8800 |
| Business Description | The company is a specialty pharmaceutical company that develops new drugs and improved formulations of existing drugs using our proprietary porous microparticle technology. |
|
Filing Information IPO has been | |||
| To Trade As | ACUS (NASNTL) | Industry | Pharmaceutical (SIC 2834) |
| Type of Stock Offered | Common Shares | Filing Date | 9/4/2001 |
| Domestic Shares Filed | 0 | Filing Price | - - |
| Foreign Shares Filed | 0 | Offering Amount | $60,000,000 |
| Company Shares | 0 | Est. Expenses | - - |
| Selling Shrhldrs Shares | 0 | Post-IPO Shares | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Thomas Weisel Partners LLC | Lead Manager | (415) 364-2500 |
| First Union Capital Markets Corp. | Co-manager | (804) 649-2311 |
| UBS Warburg LLC | Co-manager |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 6 Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/1996 | 12/31/1997 | 12/31/1998 | 12/31/1999 | 12/31/2000 | 6/30/2000 | 6/30/2001 |
| Revenues | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
| Income from Oper. | - | - | - | - | - | - | - |
| Net Income | -2.634 | -4.943 | -9.415 | -9.141 | -24.429 | -17.609 | -7.783 |
| E.P.S | -1.320 | -2.560 | -4.720 | -4.540 | -10.700 | -7.220 | -3.760 |
| Revenue Growth (%) | - | - | - | - | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -9.32 | -4.93 | -7.42 | ||||
| Cash Flow - Inv. | -32.77 | -12.22 | 6.42 | ||||
| Cash Flow - Fin. | 45.18 | 30.54 | 4.17 | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| As of: - - | Financial Ratios | ||||
| Total Assets | - | Current Assets | - | Current Ratio | - |
| Total Liab. | 0.00 | Current Liab. | - | Debt Ratio | - |
| Total Equity | - | Working Cap. | - | Debt to Equity Ratio | - |
| Cash | - | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for research and development activities, including clinical trials, working capital and other general corporate purposes. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Testa, Hurwitz & Thibeault |
| Bank's Law Firm | Hale and Dorr |
| Auditor | Arthur Andersen |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Thomas Weisel group | 15.30 | |
| Burr, Egan, Deleage group | 11.30 | |
| Elan International Services, Ltd. | 9.80 | |
| Bank of America group | 9.70 | |
| Polaris Venture Partners group | 6.50 | |
| Prism Venture Partners I, L.P. | 5.70 | |
| Note: represents ownership of 5% or more prior to the offering. | ||